Inhibiting G protein βγ signaling blocks prostate cancer progression and enhances the efficacy of paclitaxel

Oncotarget. 2017 May 30;8(22):36067-36081. doi: 10.18632/oncotarget.16428.

Abstract

Aberrant activation of G protein-coupled receptors (GPCRs) is implicated in prostate cancer progression, but targeting them has been challenging because multiple GPCRs are involved in cancer progression. In this study, we tested the effect of blocking signaling via a hub through which multiple GPCRs converge - the G-protein Gβγ subunits. Inhibiting Gβγ signaling in several castration-resistant prostate cancer cell lines (i.e. PC3, DU145 and 22Rv1), impaired cell growth and migration in vitro, and halted tumor growth and metastasis in nude mice. The blockade of Gβγ signaling also diminished prostate cancer stem cell-like activities, by reducing tumorsphere formation in vitro and tumor formation in a limiting dilution assay in nude mice. Furthermore, Gβγ blockade enhanced the sensitivity of prostate cancer cells to paclitaxel treatment, both in vitro and in vivo. Together, our results identify a novel function of Gβγ in regulating prostate cancer stem-cell-like activities, and demonstrate that targeting Gβγ signaling is an effective approach in blocking prostate cancer progression and augmenting response to chemotherapy.

Keywords: G protein-coupled receptors; Gβγ; cancer stem cells; prostate cancer growth and metastasis.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Carcinogenesis
  • Cell Growth Processes
  • Cell Line, Tumor
  • Cell Movement
  • Drug Resistance, Neoplasm
  • GTP-Binding Protein alpha Subunits / genetics
  • GTP-Binding Protein alpha Subunits / metabolism
  • GTP-Binding Protein beta Subunits / metabolism*
  • GTP-Binding Protein gamma Subunits / metabolism*
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Neoplastic Stem Cells / physiology*
  • Paclitaxel / therapeutic use*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / metabolism*
  • Signal Transduction
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • GTP-Binding Protein alpha Subunits
  • GTP-Binding Protein beta Subunits
  • GTP-Binding Protein gamma Subunits
  • Paclitaxel